Multiple Myeloma News and Research

RSS

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.

Mayo Clinic researchers examine potential new CAR-T cell treatment for multiple myeloma

Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma.

28 Jun 2021

Study identifies new epigenetic control pathways in multiple myeloma growth

An international group of researchers from Japan, the United States, and the UK studied the role of the histone demethylase KDM5A in multiple myeloma.

18 May 2021

Low representation of minority groups in genomic databases may impact therapy selection

Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.

22 Mar 2021

Genome architectural changes linked to B cell-related blood cancers

Flaws in the way chromosomes are packed into antibody-producing B-cells seem to play a key role in the development of B-cell-related blood cancers.

2 Feb 2021

Two enzymes drive pre-cancer stem cells into malignancy

Since stem cells can continually self-regenerate, making more stem cells, and differentiate into many different specialized cell types, they play an important role in our development and health.

27 Jan 2021

Investigational antisense medicine lowers disease burden, reduces myeloma cell abundance in mice

Many patients with multiple myeloma, a type of blood cancer, eventually develop resistance to one treatment after another. That's in part because cancer stem cells drive the disease -- cells that continually self-renew. If a therapy can't completely destroy these malignant stem cells, the cancer is likely to keep coming back.

21 Jan 2021

Researchers create molecular ON-OFF switches to regulate CAR T cell activity

CAR T cells are a breakthrough class of effective but often toxic cancer therapies. To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug.

7 Jan 2021

Subcutaneous injection of teclistamab drug shows promise in treating aggressive multiple myeloma

A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma, according to findings from a multi-institutional phase I study being presented by Alfred L. Garfall, MD, an assistant professor of Medicine in the division of Hematology-Oncology in the Perelman School of Medicine at the University of Pennsylvania, at the annual American Society of Hematology & Exposition Meeting on Dec. 5 (abstract #180).

7 Dec 2020

MIT engineers develop a method to turn off specific genes in bone marrow cells

Using specialized nanoparticles, MIT engineers have developed a way to turn off specific genes in cells of the bone marrow, which play an important role in producing blood cells.

6 Oct 2020

Researchers find new way to create natural compound that shows promise as anti-cancer agent

Scripps Research chemists Hans Renata, PhD, and Alexander Adibekian, PhD, have discovered a way to efficiently create a synthetic version of a valuable natural compound called cepafungin I, which has shown promise as an anti-cancer agent.

7 Aug 2020

A safer treatment harnesses the body's cancer-fighting T cells to fight multiple myeloma

A treatment for multiple myeloma that harnesses the body's cancer-fighting T cells was safe in humans and showed preliminary signs of effectiveness, according to a clinical trial involving 23 patients with relapsed or treatment-resistant disease.

30 Jul 2020

Genome sequencing reveals signposts in DNA for cancer, disease risk

By sequencing entire genomes for DNA modifications, and analyzing both cancer tissues and healthy ones, Hackensack Meridian Health researchers and doctors have found what could be a key to risks for cancer and other diseases: specific locations in the DNA where those expression changes (methylation) are imbalanced, according to a new publication.

30 Jun 2020

Immune System Changes Occur Early In Development Of Multiple Myeloma

Before multiple myeloma becomes a malignant disease, the collection of immune system cells and signal carriers amid the tumor cells undergo dramatic shifts.

29 Apr 2020

Applying integrated lipidomics and proteomics in multiple myeloma reveals potential disease pathways

A team of Australian researchers has confirmed the feasibility and potential of applying integrated lipidomics and proteomics to malignant plasma cells from myeloma patients.

13 Feb 2020